loading
Outlook Therapeutics Inc stock is traded at $1.53, with a volume of 132.07K. It is down -1.61% in the last 24 hours and up +8.93% over the past month. Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
See More
Previous Close:
$1.55
Open:
$1.57
24h Volume:
132.07K
Relative Volume:
0.27
Market Cap:
$47.30M
Revenue:
-
Net Income/Loss:
$-51.50M
P/E Ratio:
-0.3825
EPS:
-4
Net Cash Flow:
$-47.10M
1W Performance:
+5.17%
1M Performance:
+8.93%
6M Performance:
-71.97%
1Y Performance:
-81.38%
1-Day Range:
Value
$1.51
$1.58
1-Week Range:
Value
$1.40
$1.68
52-Week Range:
Value
$0.87
$9.2899

Outlook Therapeutics Inc Stock (OTLK) Company Profile

Name
Name
Outlook Therapeutics Inc
Name
Phone
(609) 619-3990
Name
Address
111 S. WOOD AVENUE, ISELIN, NJ
Name
Employee
23
Name
Twitter
Name
Next Earnings Date
2024-08-14
Name
Latest SEC Filings
Name
OTLK's Discussions on Twitter

Compare OTLK with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
OTLK
Outlook Therapeutics Inc
1.53 47.30M 0 -51.50M -47.10M -4.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.08 125.74B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
596.99 61.57B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
609.69 36.40B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.17 30.36B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
247.49 24.89B 3.81B -644.79M -669.77M -6.24

Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-02-24 Downgrade Chardan Capital Markets Buy → Neutral
Mar-27-24 Upgrade BTIG Research Neutral → Buy
Feb-15-24 Upgrade Chardan Capital Markets Neutral → Buy
Jan-25-24 Upgrade Guggenheim Neutral → Buy
Dec-27-23 Upgrade CapitalOne Equal Weight → Overweight
Aug-31-23 Downgrade Chardan Capital Markets Buy → Neutral
Aug-31-23 Downgrade H.C. Wainwright Buy → Neutral
Aug-30-23 Downgrade BTIG Research Buy → Neutral
Aug-30-23 Downgrade Cantor Fitzgerald Overweight → Neutral
Aug-30-23 Downgrade CapitalOne Overweight → Equal Weight
Aug-30-23 Downgrade Guggenheim Buy → Neutral
Jul-13-23 Initiated CapitalOne Overweight
Apr-03-23 Initiated Guggenheim Buy
Feb-06-23 Initiated Cantor Fitzgerald Overweight
Oct-31-22 Initiated BTIG Research Buy
Sep-13-22 Initiated Chardan Capital Markets Buy
Sep-11-19 Initiated Ladenburg Thalmann Buy
May-16-19 Initiated Oppenheimer Outperform
Apr-22-19 Initiated Ascendiant Capital Markets Buy
View All

Outlook Therapeutics Inc Stock (OTLK) Latest News

pulisher
Apr 21, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 21, 2025
pulisher
Apr 19, 2025

Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD - ADVFN

Apr 19, 2025
pulisher
Apr 17, 2025

Age Related Vision Dysfunction Market to Reach New Heights - openPR.com

Apr 17, 2025
pulisher
Apr 17, 2025

Age Related Vision Dysfunction Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Kodiak Sciences Inc., Outlook Therapeutics, Eye point Pharmaceuticals - The Globe and Mail

Apr 17, 2025
pulisher
Apr 12, 2025

25,615 Shares in Outlook Therapeutics, Inc. (NASDAQ:OTLK) Acquired by Commonwealth Equity Services LLC - Defense World

Apr 12, 2025
pulisher
Apr 11, 2025

Outlook Therapeutics Approves Retention Incentive for CFO - MSN

Apr 11, 2025
pulisher
Apr 10, 2025

Henlius And Outlook Move Forward With Ophthalmic Bevacizumab - insights.citeline.com

Apr 10, 2025
pulisher
Apr 10, 2025

Guggenheim maintains Buy on Outlook Therapeutics, target $10 By Investing.com - Investing.com Canada

Apr 10, 2025
pulisher
Apr 09, 2025

INVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Outlook Therapeutics, Inc.(OTLK) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire

Apr 09, 2025
pulisher
Apr 09, 2025

FDA accepts updated biologics license application from Outlook Therapeutics for ONS-5010 for the treatment of wet AMD - Optometry Times

Apr 09, 2025
pulisher
Apr 09, 2025

Guggenheim maintains Buy on Outlook Therapeutics, target $10 - Investing.com

Apr 09, 2025
pulisher
Apr 08, 2025

FDA sets August 27 review date for Outlook Therapeutics’ eye drug By Investing.com - Investing.com South Africa

Apr 08, 2025
pulisher
Apr 08, 2025

Outlook Therapeutics Says FDA Acknowledged Receipt Of Co's BLA ResubmissionSEC Filing - marketscreener.com

Apr 08, 2025
pulisher
Apr 08, 2025

Outlook Therapeutics (OTLK) Soars After FDA Accepts ONS-5010 for Review - GuruFocus

Apr 08, 2025
pulisher
Apr 08, 2025

OTLKWOutlook Therapeutics Inc Latest Stock News & Market Updates - Stock Titan

Apr 08, 2025
pulisher
Apr 08, 2025

Outlook Therapeutics gets FDA review acceptance for wet AMD treatment - Seeking Alpha

Apr 08, 2025
pulisher
Apr 08, 2025

Outlook Therapeutics Says FDA Accepts Biologics License Application for Wet AMD Treatment - MarketScreener

Apr 08, 2025
pulisher
Apr 08, 2025

FDA sets August 27 review date for Outlook Therapeutics' eye drug - Investing.com

Apr 08, 2025
pulisher
Apr 08, 2025

FDA sets August 27 review date for Outlook Therapeutics’ eye drug - Investing.com India

Apr 08, 2025
pulisher
Apr 08, 2025

Outlook Therapeutics Resubmits BLA For ONS-5010 In Wet AMD - Nasdaq

Apr 08, 2025
pulisher
Apr 08, 2025

Outlook Therapeutics® Announces Acceptance of Biologics - GlobeNewswire

Apr 08, 2025
pulisher
Apr 08, 2025

Major FDA Milestone: Novel Wet AMD Drug Gets Review Date, Could Be First-of-its-Kind Approval - Stock Titan

Apr 08, 2025
pulisher
Apr 02, 2025

Charles Schwab Investment Management Inc. Sells 15,411 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World

Apr 02, 2025
pulisher
Mar 31, 2025

Outlook Therapeutics, Inc. (NASDAQ:OTLK) Shares Bought by Bank of New York Mellon Corp - Defense World

Mar 31, 2025
pulisher
Mar 22, 2025

Head-To-Head Comparison: Cabaletta Bio (NASDAQ:CABA) vs. Outlook Therapeutics (NASDAQ:OTLK) - Defense World

Mar 22, 2025
pulisher
Mar 20, 2025

Outlook Therapeutics Files Prospectus Covering Offer & Resale By Selling Stockholders Of Up To 21.7 Million Shares Of Common Stock - Marketscreener.com

Mar 20, 2025
pulisher
Mar 15, 2025

Outlook Therapeutics expands share authorization - Investing.com Australia

Mar 15, 2025
pulisher
Mar 14, 2025

Outlook Therapeutics Issues Convertible Note to Avondale - TipRanks

Mar 14, 2025
pulisher
Mar 14, 2025

Outlook Therapeutics expands share authorization By Investing.com - Investing.com UK

Mar 14, 2025
pulisher
Mar 10, 2025

Rhumbline Advisers Purchases 174,896 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World

Mar 10, 2025
pulisher
Mar 03, 2025

SHAREHOLDER ALERT: Potential Recovery for Outlook Therapeutics, Inc. (OTLK) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 03, 2025

SHAREHOLDER ALERT: Contact Levi & Korsinsky Before January 2, 2024 to Discuss Your RightsOTLK - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 03, 2025

INVESTOR ALERT: Contact Levi & Korsinsky Before January 2, 2024 to Discuss Your RightsOTLK - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 03, 2025

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Outlook Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineOTLK - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 01, 2025

Outlook Therapeutics® Re-Submits Biologics License - GlobeNewswire

Mar 01, 2025
pulisher
Feb 28, 2025

Outlook Therapeutics Resubmits BLA For ONS-5010, A Proposed Treatment For Wet AMD - Nasdaq

Feb 28, 2025
pulisher
Feb 28, 2025

Outlook Therapeutics Resubmits Biologics License Application By Investing.com - Investing.com South Africa

Feb 28, 2025
pulisher
Feb 28, 2025

Outlook Therapeutics Resubmits BLA For ONS-5010 To FDA In Wet AMD - Nasdaq

Feb 28, 2025
pulisher
Feb 28, 2025

Outlook Therapeutics Resubmits Biologics License Application - Investing.com

Feb 28, 2025
pulisher
Feb 28, 2025

Can Outlook's Eye Treatment Win FDA Approval Despite Missing Primary Endpoint? - StockTitan

Feb 28, 2025
pulisher
Feb 27, 2025

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Outlook Therapeutics, Inc.(OTLK) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 27, 2025

SHAREHOLDER ALERT: Levi & Korsinsky Reminds Outlook Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 2, 2024 – OTLK - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 25, 2025

Outlook Therapeutics (NASDAQ:OTLK) Given New $24.00 Price Target at Ascendiant Capital Markets - Defense World

Feb 25, 2025
pulisher
Feb 24, 2025

HC Wainwright Issues Pessimistic Forecast for OTLK Earnings - MarketBeat

Feb 24, 2025
pulisher
Feb 23, 2025

Equities Analysts Offer Predictions for OTLK Q1 Earnings - MarketBeat

Feb 23, 2025
pulisher
Feb 21, 2025

vTv Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:VTVT - Benzinga

Feb 21, 2025
pulisher
Feb 21, 2025

HC Wainwright Has Pessimistic Outlook of OTLK Q2 Earnings - Defense World

Feb 21, 2025
pulisher
Feb 20, 2025

What is HC Wainwright’s Estimate for OTLK Q1 Earnings? - Defense World

Feb 20, 2025

Outlook Therapeutics Inc Stock (OTLK) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.39
price down icon 0.63%
$68.60
price down icon 0.25%
$32.01
price down icon 0.09%
$34.64
price down icon 7.28%
$114.80
price down icon 4.57%
biotechnology ONC
$248.25
price down icon 2.59%
Cap:     |  Volume (24h):